ROUTiNE: Resuscitation Outcomes in the Netherlands

Sponsor
Erasmus Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT03120507
Collaborator
(none)
700
12
29.9
58.3
1.9

Study Details

Study Description

Brief Summary

The Resuscitation Outcomes in the Netherlands - study assesses one-year survival and quality of life after In-Hospital Cardiac Arrest(IHCA). It's design is a multicenter prospective observational cohort study which will include all patients undergoing cardiopulmonary resuscitation (CPR) for IHCA in 2017. Current literature describes poor survival after IHCA and no risk stratification tool for long-term outcome is available. Furthermore no such study has ever been performed in the Netherlands. The investigators aim to gain further insight in this major adverse event.

Detailed Description

Background: In-hospital cardiac arrest (IHCA) is a serious adverse event for which cardiopulmonary resuscitation (CPR) can be performed to restore circulation. Currently survival after IHCA is poor. To assess the success of resuscitation attempts there is a need for research that focuses on long-term survival and quality of life. Patient selection for CPR, prevention of cardiac arrest and improvement of CPR techniques are crucial for improving qualitative survival. To assess the feasibility of this project a single-center retrospective cohort study was conducted over a 10-year period in the OLVG hospital. For all patients who received CPR survival to discharge was 32% and one-year survival was 22%. This is slightly higher than survival reported in contemporary literature. Due to it's design no prognostic variables could be derived from this study, however data suggested age and Charlson Comorbidity Index could prove useful in predicting long-term outcome. In the consecutive year this study was designed.

Hypothesis: The hypothesis is that one-year survival after IHCA in Dutch hospitals is poor, consistent with international literature and our feasibility trial, and survival can be improved through selection, prevention and training.

Objective: The main objective of this study is to assess the one-year survival of patients after CPR for in-hospital cardiac arrest. The secondary objectives are to assess quality of life and functional status after successful CPR. Furthermore the investigators aim to assess if there are patient-related predicting factors for these outcome measures and to assess whether outcomes are influenced by hospital-related factors (i.e. CPR training and treatment options).

Study design: The current study has a prospective, observational design, with a 12-month follow-up. Patients will be included from January 1st 2017. Patient data collection will take place at four time points: T0= directly post-CPR, T1= at hospital discharge or at in-hospital death, T2= 3 months after CPR, T3= 12 months after CPR. Clinical data will be collected at all time points. Quality of life data will be collected at T2 and T3 by means of validated questionnaires. We will assess functional status through questionnaires and link these to pre-existing and acquired comorbidities (e.g. stroke). General hospital data and data concerning the level of CPR-training will be ascertained at four moments during the first year of patient inclusion.

Study population: An estimated six hundred patients of 18 years or older who will receive CPR for cardiac arrest in the participating hospitals. This will include all cases of in-hospital cardiac arrest, also including Operation Room (OR), Intensive/Coronary Care Unit (ICU/CCU) and Emergency Department (ER). Patients in whom CPR was started before arrival in hospital will be excluded.

Expected results: The main study endpoints are one-year survival and quality of life. Secondary endpoints are direct survival and survival to discharge. The first preliminary results are expected in the first quarter of 2018. After conclusion of this project the investigators of this project aim to develop recommendations that will improve survival after IHCA.

Study Design

Study Type:
Observational
Actual Enrollment :
700 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Resuscitation Outcomes in the Netherlands Study
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Jun 1, 2019
Actual Study Completion Date :
Jul 1, 2019

Outcome Measures

Primary Outcome Measures

  1. one-year survival [one year]

    Survival one year after in-hospital cardiac arrest

Secondary Outcome Measures

  1. SF-12 [3 months and one year after in-hospital cardiac arrest]

    Quality of life measured by SF-12 questionnaire

  2. EuroQoL [3 months and one year after in-hospital cardiac arrest]

    Quality of life measured by EuroQoL questionnaire

  3. HADS [3 months and one year after in-hospital cardiac arrest]

    Quality of life measured by Hospital Anxiety and Depression Scale questionnaire

  4. Charlson Comorbidity Index [3 months and one year after in-hospital cardiac arrest]

    Development of new comorbidities as defined by the Charlson Comorbidity Index.

  5. Cardiovascular events [3 months and one year after in-hospital cardiac arrest]

    Development of new cardiovascular events (e.g. myocardial infarction, stroke), by means of checkbox question.

  6. Working life [Prior to in-hospital cardiac arrest and 3 months and one year after in-hospital cardiac arrest]

    Participation in working life; status before cardiac arrest and after by means of checkbox question.

  7. TICS [3 months after in-hospital cardiac arrest, if patients are not able to respond to regular questionnaires (paper)]

    Telephonic interview for Cognitive Status

  8. CSI [3 months and one year after in-hospital cardiac arrest]

    Caregiver strain index for caregivers of In-Hospital Cardiac Arrest Survivors

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients over 18 years of age

  • Receiving cardiopulmonary resuscitation, as defined by starting manual chest compressions, for a circulatory arrest occuring in-hospital.

  • In hospital is defined as all hospital wards, departments, outpatient clinics, and hallways.

Exclusion Criteria:
  • Children (<18 years of age)

  • Purposely induced cardiac arrest (e.g. cardiac surgery)

  • Purposely induced arrhythmias (e.g. electrophysiological treatment)

  • Refusal to participate

  • Primary out-of-hospital cardiac arrest with re-arrest <24h after hospital admission.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rijnstate Ziekenhuis Arnhem Gelderland Netherlands 6815AD
2 OLVG Amsterdam Noord-Holland Netherlands 1091AC
3 Deventer Ziekenhuis Deventer Overijssel Netherlands 7416SE
4 Medisch Spectrum Twente Enschede Overijssel Netherlands 7512KZ
5 Isala klinieken Zwolle Overijssel Netherlands 8025AB
6 ZorgSaam Zeeuws-Vlaanderen Terneuzen Zeeland Netherlands 4535PA
7 Amphia Ziekenhuis Breda Zuid-Holland Netherlands 4818CK
8 Reinier de Graaf Gasthuis Delft Zuid-Holland Netherlands 2625AD
9 Albert Schweitzer Ziekenhuis Dordrecht Zuid-Holland Netherlands 3318AT
10 Sint Franciscus Vlietland Groep Rotterdam Zuid-Holland Netherlands 3045PM
11 Maasstad Ziekenhuis Rotterdam Zuid-Holland Netherlands 3079DZ
12 Haaglanden Medisch Centrum The Hague Zuid-Holland Netherlands

Sponsors and Collaborators

  • Erasmus Medical Center

Investigators

  • Principal Investigator: Robert Jan Stolker, MD PhD, Erasmus Medical Center
  • Principal Investigator: Marc Schluep, MD, Erasmus Medical Center
  • Study Chair: Sanne Hoeks, PhD, Erasmus Medical Center
  • Study Chair: Henrik Endeman, MD PhD, OLVG

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Marc Schluep, Principal Investigator, Erasmus Medical Center
ClinicalTrials.gov Identifier:
NCT03120507
Other Study ID Numbers:
  • ABR55661.078.16
  • NTR6145
  • MEC-2016-563
First Posted:
Apr 19, 2017
Last Update Posted:
Jul 16, 2019
Last Verified:
Jul 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Marc Schluep, Principal Investigator, Erasmus Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 16, 2019